Analysis of Drug Resistance in Children Receiving Antiretroviral Therapy for Treatment of HIV-1 Infection in Uganda

Simple item page
dc.contributor.authorTowler, William I.
dc.contributor.authorBarlow-Mosha, Linda
dc.contributor.authorChurch, Jessica D.
dc.contributor.authorBagenda, Danstan
dc.contributor.authorAjuna, Patrick
dc.contributor.authorMubiru, Micheal
dc.contributor.authorMusoke, Philippa
dc.contributor.authorEshleman, Susan H.
dc.date.accessioned2021-12-15T09:04:44Z
dc.date.available2021-12-15T09:04:44Z
dc.date.issued2010
dc.description.abstractWe analyzed drug resistance in HIV-infected Ugandan children who received antiretroviral therapy in a prospective, observational study (2004–2006); some children had prior single-dose nevirapine (sdNVP) exposure. Children received stavudine (d4T), lamivudine (3TC), and nevirapine (NVP); treatment was continued if they were clinically and immunologically stable. Samples with >1,000 copies=ml HIV RNA were analyzed by using the ViroSeq HIV Genotyping System (ViroSeq). Subtype A and D pretreatment samples also were analyzed with the LigAmp assay (for K103N, Y181C, and G190A). ViroSeq results were obtained for 74 pretreatment samples (35 from sdNVP-exposed children (median age, 19 months) and 39 from sdNVP-unexposed children (median age, 84 months). This included 39 subtype A, 22 subtype D, 1 subtype C, and 12 inter-subtype recombinant samples. One sample had nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance, one had nucleoside reverse transcriptase inhibitor (NRTI) resistance, and three had protease inhibitor (PI) resistance. Y181C was detected by using LigAmp in five pretreatment samples [four (14.8%) of 37 samples from sdNVP-exposed children, one (4.2%) of 24 samples from children without prior sdNVP exposure; p¼0.35]. Among children who were not virally suppressed at 48 weeks of treatment, all 12 tested had NNRTI resistance, as well as resistance to 3TC and emtricitibine (FTC); three had resistance to other NRTIs. Seven of those children had a ViroSeq result at 96 weeks of treatment; four of the seven acquired resistance to additional NRTIs by 96 weeks. In Uganda, clinically and immunologically stable children receiving nonsuppressive antiretroviral treatment regimens are at risk for development of drug resistance.en_US
dc.identifier.citationTowler, W. I., Barlow-Mosha, L., Church, J. D., Bagenda, D., Ajuna, P., Mubiru, M., ... & Eshleman, S. H. (2010). Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda. AIDS research and human retroviruses, 26(5), 563-568.DOI: 10.1089/aid.2009.0164en_US
dc.identifier.issn10.1089/aid.2009.0164
dc.identifier.other10.1089/aid.2009.0164
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/552
dc.language.isoenen_US
dc.publisherAIDS research and human retrovirusesen_US
dc.subjectDrug Resistanceen_US
dc.subjectChildrenen_US
dc.subjectAntiretroviral Therapyen_US
dc.subjectTreatment of HIVen_US
dc.subjectInfectionen_US
dc.titleAnalysis of Drug Resistance in Children Receiving Antiretroviral Therapy for Treatment of HIV-1 Infection in Ugandaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Analysis of Drug Resistance in Children Receiving Antiretroviral Therapy for Treatment of HIV-1 Infection in Uganda.pdf
Size:
82.47 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences